Ascentage Pharma's issued share capital increases by 648,510 shares

Ascentage Pharma Group International's monthly return for September 2025 reveals an increase in its issued share capital. The total number of issued shares (excluding treasury shares) rose by 648,510, bringing the new total to 373,319,722 shares. The company’s authorized share capital remained stable at $50,000, with 500,000,000 ordinary shares authorized at a par value of $0.0001 per share.

The increase in issued shares primarily stems from movements related to the company's RSU (Restricted Share Unit) Schemes. Specifically, 648,510 new shares were issued during the month pursuant to these arrangements. As of September 30, 2025, there are 2,154,197 Pre-IPO Share Option Scheme options outstanding, with 966,880 shares remaining available for future issuance under this scheme.

Additionally, the company reported no changes in its treasury shares for the month. The maximum number of RSUs that may be granted under the 2021 RSU Scheme is 3,133,526 shares, and under the 2022 RSU Scheme is 11,072,695 shares.